Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Muscle Wasting and Metabolic Syndrome Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MSTN (Myostatin / GDF8) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MSTN Mature Domain, Propeptide & Latent Complex Recombinant Protein (ECD-Fc / Active Mature Protein available). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View MSTN Products |
| Gene Delivery | MSTN Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View MSTN Products |
| Benchmark Ab | Anti-MSTN (Sequence of Apitegromab / Domagrozumab / Tredegumab). Recombinant positive control. | View MSTN Products |
| Validator | MSTN siRNA Set. For knockdown verification. | View MSTN Products |
| Related Target: ACVR2B / ActRIIB | Activin Receptor Type IIB. Primary receptor for MSTN; ECD-Fc for binding/blockade assays. | View ACVR2B Products |
| Related Target: GDF11 | Growth Differentiation Factor 11. Closest homolog; essential for counter-screening off-target liability. | View GDF11 Products |
| Related Target: FST (Follistatin) | Endogenous inhibitor and PD biomarker. | View FST Products |
Critical Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GDF11 Selectivity (85% homology) | Human MSTN vs GDF11 ortholog proteins available with >95% purity for cross-reactivity ELISA/SPR; strict mass spec verification. |
| Active vs Latent Form Discrimination | Prodomain-free mature MSTN and latent complex (prodomain+MSTN) variants for mechanism-specific binding; HEK293 expressed. |
| Receptor Competition (ACVR2B) | High-affinity MSTN protein validated for C2C12 myoblast differentiation inhibition assays. |
| Cross-species PK/PD modeling | Human/Mouse/Cyno MSTN proteins with conserved disulfide bridge pattern. |
| Lack of Positive Controls | Clinical Benchmark Antibodies (biosimilars) included with strictly sequence-verified variable regions. |
| False Positives Minimization | Validated siRNA included for specificity checks in cell-based assays. |
Live MSTN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MSTN therapeutics is intensifying, with major players shifting focus from traditional muscle dystrophy treatments to combining MSTN inhibitors with GLP-1 receptor agonists. As first-generation therapies reach the clinic, the next wave of R&D is targeting the preservation of lean muscle mass during rapid, medically induced weight loss. Highly specific targeting of the latent MSTN complex, rather than the mature active form, has emerged as a crucial strategy to minimize systemic off-target effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Latent) | Scholar Rock (Apitegromab) | SMA, Obesity (Combo) | Conformation Assay (Need high-purity Pro-complex vs Mature forms) |
| Receptor Decoy/Fusion | Biohaven, Lilly | Obesity, Muscle Wasting | Binding Kinetic Assay (Need High-Purity ActRIIB ECD) |
| Bispecific / Dual Targeting | Regeneron | Metabolic Syndrome | Heterodimer Validation (Need Cross-reactive Abs & Antigens) |
| Small Mol / Peptides | Various Biotechs | Sarcopenia | Selectivity Assay (Need Homolog Panel: GDF11, Activin A) |